Bank of New York Mellon Corp Purchases 31,505 Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO)

Bank of New York Mellon Corp boosted its holdings in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 13.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 274,635 shares of the medical instruments supplier’s stock after purchasing an additional 31,505 shares during the quarter. Bank of New York Mellon Corp owned about 0.63% of Harvard Bioscience worth $783,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Price T Rowe Associates Inc. MD bought a new stake in shares of Harvard Bioscience in the 1st quarter worth about $54,000. Hillsdale Investment Management Inc. acquired a new position in shares of Harvard Bioscience in the 1st quarter valued at $112,000. Riverwater Partners LLC increased its stake in Harvard Bioscience by 13.7% during the 2nd quarter. Riverwater Partners LLC now owns 105,977 shares of the medical instruments supplier’s stock worth $302,000 after purchasing an additional 12,780 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Harvard Bioscience by 38.7% in the 1st quarter. BNP Paribas Financial Markets now owns 75,970 shares of the medical instruments supplier’s stock valued at $322,000 after purchasing an additional 21,183 shares during the period. Finally, Corsair Capital Management L.P. bought a new stake in Harvard Bioscience in the 4th quarter valued at approximately $356,000. Institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Price Performance

NASDAQ:HBIO opened at $2.75 on Monday. Harvard Bioscience, Inc. has a 52-week low of $2.50 and a 52-week high of $5.56. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.94 and a current ratio of 2.05. The stock’s 50-day simple moving average is $2.99 and its 200 day simple moving average is $3.36. The company has a market cap of $119.43 million, a P/E ratio of -13.75 and a beta of 1.30.

Harvard Bioscience (NASDAQ:HBIO) last announced its earnings results on Thursday, August 8th. The medical instruments supplier reported ($0.03) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.06). The company had revenue of $23.10 million for the quarter, compared to the consensus estimate of $29.91 million. Harvard Bioscience had a negative return on equity of 2.70% and a negative net margin of 10.56%. As a group, sell-side analysts forecast that Harvard Bioscience, Inc. will post 0.11 EPS for the current fiscal year.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.